Abstract
We monitored both chromogranin A (CgA) and neuron specific enolase (NSE) in serial serum specimens from 14 patients with prostate cancer (CAP patients) showing resistance to hormonal treatment. Elevated serum CgA was detected in 10 out of these 14 patients (71%) during treatment, and an early appearance of elevated serum CgA was found in 6 of 14 (43%) of these patients when serum tPSA levels were still in the normal range. If patients with radical prostatectomy were not included, the percentage of patients showing an early appearance of elevated serum CgA would have been much higher. Elevated serum CgA levels also were found in patients not subject to hormonal therapy. Serial specimens from two out of three prostate cancer patients, randomly selected, contained elevated serum CgA. Serum NSE was not detectable in any of the serial specimens we studied, suggesting that CgA, not NSE, should be used as a marker for neuroendocrine differentiation. We also compared the serum CgA in random serum specimens between patients with BPH (benign prostate hyperplasia) and with prostate cancer in the concentration range of serum tPSA between 3–15 ng/mL. Although serum CgA concentrations in BPH patients overlapped considerably with those levels in patients with prostate cancer, levels > 100 ng/mL should suggest prostate cancer. The early appearance of elevated serum CgA allows an early change of therapy to be made and can lead to the effective prevention of any further development of metastases. J. Clin. Lab. Anal. 12:20–25, 1998. © 1998. Wiley‐Liss, Inc.
Keywords: BPH, metastases, neuroendocrine cell, neuroendocrine differentiation, NSE, PSA
References
- 1. di Sant'Agnese PA, Cockett ATK: Neuroendocrine differentiation in prostatic malignancy. Cancer 78: 357–361, 1996. [DOI] [PubMed] [Google Scholar]
- 2. Tetu B, Ro JY, Ayala AF, Johnson DE, Logothetis CJ, Ordonez NG: Small cell carcinoma of the prostate: Part I. A clinicopathologic study of 20 cases. Cancer 59: 1803, 1987. [DOI] [PubMed] [Google Scholar]
- 3. di Sant'Agnese PA, Cockett ATK: The prostatic endocrine‐paracrine (Neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: A review and future directions in basic research. J Urol 152: 1927–1937, 1994. [DOI] [PubMed] [Google Scholar]
- 4. di Sant'Agnese PA: Neuroendocrine differentiation in prostatic carcinoma. Recent findings and new concepts. Cancer 75: 1850–1859, 1995. [Google Scholar]
- 5. Cussenot O, Villette JM, Valeri A, Cariou G, Descrandschamps F, Cortesse A, Meria P, Teillac P, Fiet J, Le Due A: Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. J Urol 155: 1340–1343, 1966. [PubMed] [Google Scholar]
- 6. Kadmon D, Thompson TC, Lynch GR, Scardino PT: Elevated plasma chromogranin‐A concentrations in prostatic carcinoma. J Urol 146: 358–361, 1991. [DOI] [PubMed] [Google Scholar]
- 7. Angelsen A, Syversen U, Haugen OA, Stridsberg M, Kjolnerod OK, Waldum HL: Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 30: 1–6, 1997. [DOI] [PubMed] [Google Scholar]
- 8. Cockett ATK, Di Sant'Agnese PA, Gopinath P, Schoen S, Abrahamsson PA: Relationship on neuroendocrine cells of prostate and serotonin to benign prostatic hyperplasia. Urology 42: 512, 1993. [DOI] [PubMed] [Google Scholar]
- 9. Hoosein NM, Logothetis CJ, Chung LW: Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC‐160 on the invasive capacity of human prostatic carcinoma cells. J Urol 149: 1209–1213, 1993. [DOI] [PubMed] [Google Scholar]
- 10. Raffo AJ, Perlman H, Chen M‐W, Day ML, Streitman JS, Buttyan R: Overexpression of bcl‐2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 55: 4438–445, 1995. [PubMed] [Google Scholar]
- 11. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, Trapman J, Cleutjens K, Noordzij A, Voisakorpi T, Kallioniemi O‐P: Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 57: 314–319, 1997. [PubMed] [Google Scholar]
- 12. Tarle M, Rados N: Investigation on serum neuron‐specific enolase in prostate cancer diagnosis and monitoring: comparative study of a multiple tumor marker assay. Prostate 19: 23–27, 1991. [DOI] [PubMed] [Google Scholar]